Buyback Spend for Alnylam Pharmaceuticals (ALNY)
Buyback Spend for Alnylam Pharmaceuticals (ALNY): headline value $0. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingBuyback SpendSwitch metric
Latest period
$0
YoY change
N/A
5Y CAGR
N/A
Peak year (2014)
$15.99M
Latest annual
$0
Buyback Spend history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Buyback Spend history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $0 | — | ||
| 2024 | $0 | — | ||
| 2023 | $0 | — | ||
| 2022 | $0 | — | ||
| 2021 | $0 | — | ||
| 2020 | $0 | — | ||
| 2019 | $0 | -100.0% | ||
| 2018 | $3.47M | +1249.8% | ||
| 2017 | $257,000 | -56.9% | ||
| 2016 | $596,000 | +57.7% | ||
| 2015 | $378,000 | -97.6% | ||
| 2014 | $15.99M | +1051.3% | ||
| 2013 | $1.39M | +286.9% | ||
| 2012 | $359,000 | — | ||
| 2011 | $0 | — | ||
| 2010 | $0 | — | ||
| 2009 | $0 | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — |
Buyback Spend values are taken from Alnylam Pharmaceuticals's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Alnylam Pharmaceuticals (ALNY) buyback spend is $0.
Through 2015–2025 (10 years), Alnylam Pharmaceuticals buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Alnylam Pharmaceuticals buyback spend peaked at $15.99M in 2014; the latest annual figure is $0 in 2025 (100.0% below peak).
Across the available history, buyback spend reached its high of $15.99M in 2014 and its low of $0 in 2002.
Within Healthcare, Alnylam Pharmaceuticals (ALNY) ranks 8th among 8 peers we track. The peer median for buyback spend is $2.75B.
Alnylam Pharmaceuticals Buyback Spend by Year
Alnylam Pharmaceuticals Buyback Spend 2025: $0
Alnylam Pharmaceuticals buyback spend in 2025 was $0.
Alnylam Pharmaceuticals Buyback Spend 2024: $0
Alnylam Pharmaceuticals buyback spend in 2024 was $0.
Alnylam Pharmaceuticals Buyback Spend 2023: $0
Alnylam Pharmaceuticals buyback spend in 2023 was $0.
Alnylam Pharmaceuticals Buyback Spend 2022: $0
Alnylam Pharmaceuticals buyback spend in 2022 was $0.
Alnylam Pharmaceuticals Buyback Spend 2021: $0
Alnylam Pharmaceuticals buyback spend in 2021 was $0.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Buyback Spend
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Novo Nordisk A/S (NVO) | $1.39B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's buyback spend?
Latest reported buyback spend for Alnylam Pharmaceuticals (ALNY) is $0 (period ending December 31, 2025).
What is the long-term growth rate of Alnylam Pharmaceuticals buyback spend?
Alnylam Pharmaceuticals (ALNY) buyback spend compound annual growth rate is -100.0% over the most recent 10 years available.
When did Alnylam Pharmaceuticals buyback spend hit its highest annual value?
Alnylam Pharmaceuticals buyback spend reached its highest annual value of $15.99M in 2014.
What was Alnylam Pharmaceuticals buyback spend in 2024?
Alnylam Pharmaceuticals (ALNY) buyback spend in 2024 was $0.
What was Alnylam Pharmaceuticals buyback spend in 2025?
Alnylam Pharmaceuticals (ALNY) buyback spend in 2025 was $0.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.